You are here: Industry Insights > QBiotics

News List

Qbiotics concludes successful $85 million capital raise prnasia
June 28, 2021
QBiotics Group Limited (QBiotics), a life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals, is pleased to announce that it has concluded an $85 million capital raise, having closed the final stage of the ...
First Patient Dosed in QBiotics & MSD Clinical Trial Collaboration for Unresectable Melanoma prnasia
June 03, 2021
QBiotics Group Limited, a life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals, is pleased to announce that it has dosed the first patient in the Phase Ib/IIa clinical trial of the company's lead oncology ...
QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of Stelfonta(R) prnasia
January 20, 2020
Australian life sciences company, QBiotics Group Limited (QBiotics) is today announcing the first registration for its small molecule, tigilanol tiglate, with the European Medicines Agency (EMA) approval of STELFONTA as an oncology veterinary pharmaceutic
Publication of First In-Human Data Reveals Safety & Efficacy of Tigilanol Tiglate in Solid Tumours En-CPhI.CN
December 10, 2019
Australian life sciences company, QBiotics Group Limited (QBiotics) is announcing the publication[1] of positive results from a first in-human Phase I clinical trial of ...
QBiotics Announces First Patient Dosed in its Phase I/II Clinical Trial of Tigilanol Tiglate for Head and Neck Cancer En-CPhI.CN
December 03, 2019
QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals ...